322 related articles for article (PubMed ID: 33470499)
1. Activation of estrogen receptor beta signaling reduces stemness of glioma stem cells.
Sareddy GR; Pratap UP; Venkata PP; Zhou M; Alejo S; Viswanadhapalli S; Tekmal RR; Brenner AJ; Vadlamudi RK
Stem Cells; 2021 May; 39(5):536-550. PubMed ID: 33470499
[TBL] [Abstract][Full Text] [Related]
2. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway.
Sareddy GR; Viswanadhapalli S; Surapaneni P; Suzuki T; Brenner A; Vadlamudi RK
Oncogene; 2017 Apr; 36(17):2423-2434. PubMed ID: 27893719
[TBL] [Abstract][Full Text] [Related]
3. Tanshinone IIA inhibits the growth, attenuates the stemness and induces the apoptosis of human glioma stem cells.
Yang L; Guo H; Dong L; Wang L; Liu C; Wang X
Oncol Rep; 2014 Sep; 32(3):1303-11. PubMed ID: 24970314
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic significance of estrogen receptor β agonists in gliomas.
Sareddy GR; Nair BC; Gonugunta VK; Zhang QG; Brenner A; Brann DW; Tekmal RR; Vadlamudi RK
Mol Cancer Ther; 2012 May; 11(5):1174-82. PubMed ID: 22442308
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs).
Li X; Tao Z; Wang H; Deng Z; Zhou Y; Du Z
Exp Cell Res; 2020 Nov; 396(1):112261. PubMed ID: 32896567
[TBL] [Abstract][Full Text] [Related]
6. Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
Sareddy GR; Li X; Liu J; Viswanadhapalli S; Garcia L; Gruslova A; Cavazos D; Garcia M; Strom AM; Gustafsson JA; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2016 Apr; 6():24185. PubMed ID: 27126081
[TBL] [Abstract][Full Text] [Related]
7. Suberoylanilide hydroxamic acid represses glioma stem-like cells.
Hsu CC; Chang WC; Hsu TI; Liu JJ; Yeh SH; Wang JY; Liou JP; Ko CY; Chang KY; Chuang JY
J Biomed Sci; 2016 Nov; 23(1):81. PubMed ID: 27863490
[TBL] [Abstract][Full Text] [Related]
8. Xihuang Pill-destabilized CD133/EGFR/Akt/mTOR cascade reduces stemness enrichment of glioblastoma via the down-regulation of SOX2.
Xu L; Duan H; Zou Y; Wang J; Liu H; Wang W; Zhu X; Chen J; Zhu C; Yin Z; Zhao X; Wang Q
Phytomedicine; 2023 Jun; 114():154764. PubMed ID: 36963368
[TBL] [Abstract][Full Text] [Related]
9. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist.
He Y; Alejo S; Venkata PP; Johnson JD; Loeffel I; Pratap UP; Zou Y; Lai Z; Tekmal RR; Kost ER; Sareddy GR
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806169
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
Liu J; Viswanadhapalli S; Garcia L; Zhou M; Nair BC; Kost E; Rao Tekmal R; Li R; Rao MK; Curiel T; Vadlamudi RK; Sareddy GR
Oncotarget; 2017 Jul; 8(30):50002-50014. PubMed ID: 28654894
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
[TBL] [Abstract][Full Text] [Related]
13. The effects of type I interferon on glioblastoma cancer stem cells.
Du Z; Cai C; Sims M; Boop FA; Davidoff AM; Pfeffer LM
Biochem Biophys Res Commun; 2017 Sep; 491(2):343-348. PubMed ID: 28728846
[TBL] [Abstract][Full Text] [Related]
14. MiR-146b-5p overexpression attenuates stemness and radioresistance of glioma stem cells by targeting HuR/lincRNA-p21/β-catenin pathway.
Yang W; Yu H; Shen Y; Liu Y; Yang Z; Sun T
Oncotarget; 2016 Jul; 7(27):41505-41526. PubMed ID: 27166258
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-30a suppresses self-renewal and tumorigenicity of glioma stem cells by blocking the NT5E-dependent Akt signaling pathway.
Peng L; Ming Y; Zhang L; Zhou J; Xiang W; Zeng S; He H; Chen L
FASEB J; 2020 Apr; 34(4):5128-5143. PubMed ID: 32067282
[TBL] [Abstract][Full Text] [Related]
16. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells.
Spina R; Voss DM; Asnaghi L; Sloan A; Bar EE
Oncotarget; 2016 Jan; 7(1):459-72. PubMed ID: 26575950
[TBL] [Abstract][Full Text] [Related]
17. Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells.
Talukdar S; Das SK; Pradhan AK; Emdad L; Shen XN; Windle JJ; Sarkar D; Fisher PB
Oncotarget; 2016 Aug; 7(34):54102-54119. PubMed ID: 27472461
[TBL] [Abstract][Full Text] [Related]
18. Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling.
Hou Y; Sun B; Liu W; Yu B; Shi Q; Luo F; Bai Y; Feng H
Theranostics; 2021; 11(2):555-566. PubMed ID: 33391492
[TBL] [Abstract][Full Text] [Related]
19. Essential role of METTL3-mediated m
Visvanathan A; Patil V; Arora A; Hegde AS; Arivazhagan A; Santosh V; Somasundaram K
Oncogene; 2018 Jan; 37(4):522-533. PubMed ID: 28991227
[TBL] [Abstract][Full Text] [Related]
20. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
